

VE-821

Catalog No: tcsc0238



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1232410-49-9

Formula:

$C_{18}H_{16}N_4O_3S$

Pathway:

Cell Cycle/DNA Damage;PI3K/Akt/mTOR

Target:

ATM/ATR;ATM/ATR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

368.41


Product Description

VE-821 is a potent ATP-competitive inhibitor of **ATR** with **K_i/IC₅₀** of 13 nM/26 nM.

IC50 & Target: Ki: 13 nM (ATR)^[1]

IC50: 26 nM (ATR)^[2]

In Vitro: VE-821 shows excellent selectivity for ATR with minimal cross-reactivity against the related PIKKs ATM, DNA-PK, mTOR and PI3K γ (K_i s of 16 μ M, 2.2 μ M, >1 μ M and 3.9 μ M, respectively) and against a large panel of unrelated protein kinases^[1]. VE-821 (compound 27) also inhibits ATM and DNA-PK with IC_{50} of >8 μ M, and 4.4 μ M, respectively^[2]. VE-821 significantly enhances the sensitivity of PSN-1, MiaPaCa-2 and primary PancM pancreatic cancer cells to radiation and Gemcitabine under both normoxic and hypoxic conditions. ATR inhibition by VE-821 leads to inhibition of radiation-induced G₂/M arrest in cancer cells. In both PSN-1 and MiaPaCa-2 cells, 1 μ M VE-821 inhibits phosphorylation of Chk1 (Ser 345) after treatment with Gemcitabine (100 nM), radiation (6 Gy) or both, at 2 h post-irradiation^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!